evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,230 questions · 1,303 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 73 · 5.6%GRADE not reported 21 · 1.6%Very low 497 · 38.1%Low 403 · 30.9%Moderate 245 · 18.8%High 64 · 4.9%

Intervention not reported

HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher score indicates better quality of life. · adults following hip fracture surgery

It is very uncertain whether the intervention changes HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher… (very low certainty).

1 finding from 1 review

Intervention not reported

Mobility scales, using different mobility scales: MILA (range 0 to 36), EMS (range 0 to 20), BBS (range 0 to 56), PPME (range 0 to 12), Koval (range 1 to 7). Higher values indicate better mobility (except MILA and Koval, where scale was inverted f... · adults following hip fracture surgery

The intervention probably leads to higher mobility scales, using different mobility scales: MILA (range 0 to… (moderate certainty).

1 finding from 1 review

Any glucocorticoid vs no glucocorticoids or placebo

Clinical pregnancy rate · assisted reproduction technology cycles

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple: dosage and timing of… compared with no glucocorticoids or placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Mobility training vs control: subgroups with or without cognitive impairments

Level of functioning · older people living in the community with frailty
2 findings from 1 review

Mobility training vs control: subgroups with or without cognitive impairments

Mobility · older people living in the community with frailty
2 findings from 1 review